TG Therapeutics (NASDAQ:TGTX) Given New $22.00 Price Target at The Goldman Sachs Group

TG Therapeutics (NASDAQ:TGTX) had its target price raised by The Goldman Sachs Group from $20.00 to $22.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price indicates a potential downside of 10.57% from the stock’s current price.

TGTX has been the topic of several other research reports. TD Cowen initiated coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $36.67.

TG Therapeutics Price Performance

TG Therapeutics stock traded up $0.24 during midday trading on Tuesday, reaching $24.60. 1,201,727 shares of the stock traded hands, compared to its average volume of 3,635,380. The stock’s fifty day moving average is $23.51 and its 200-day moving average is $20.17. TG Therapeutics has a 12 month low of $9.81 and a 12 month high of $26.99. The stock has a market cap of $3.81 billion, a P/E ratio of 40.10 and a beta of 2.19. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The company had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. During the same quarter last year, the company earned $0.73 earnings per share. The company’s revenue for the quarter was down 49.4% on a year-over-year basis. As a group, equities research analysts anticipate that TG Therapeutics will post 0.13 EPS for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently modified their holdings of TGTX. NBC Securities Inc. increased its stake in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at about $35,000. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at about $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of TG Therapeutics in the 1st quarter valued at about $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.